RWE: Spain
Efficacy
PFS
ORR (1 month)
61%
CR (1 month)
29%
OS at 12 months
45%
| Safety | |
|---|---|
| CRSGrade ≥3 | 6% |
| ICANSGrade ≥3 | 4% |
“Baseline characteristics for patients prescribed Tisa-cel or other products in Spain do not differ significantly, and within this setting, results are comparable in terms of efficacy”
- Reference: 1. Kwon M et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 1742.
Data collection
Nov 2018–May 2021
Spanish Group of Stem Cell Transplantation (GETH-TC) and Spanish Group of Lymphoma and Autologous Stem Cell Transplantation (GELTAMO)
Median follow-up
months
No. of patients infused with tisa-cel
| Median age (range) years | 61 (23–76) |
| Gender (male) | 63% |
| ECOG ≥2 | 8% |
| IPI | 32% |
| HG lymphoma (double or triple hit) | 16% |
| DLBCL | 74% |
| Transformed lymphoma | 20% |
| Comorbidities | NR |
| LDH elevated | 66% |
| Prior therapies, median (IQR)≥3 lines | 2 (2–7)NR |
| Primary refractoryRefractory to last lineRelapsed | 56%NRNR |
| Prior SCTAutoAllo | 29%1% |
| Bridging therapy | 83% |
| Median vein to vein time | 51 days |
Limitations: Majority of patients (55%) were progressing prior to infusion despite bridging
- Reference: 1. Kwon M et al. American Society of Hematology Annual Meeting, 11–14 December 2021, Atlanta, GA. Abstract 1742.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete